Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

BioCentury: Amyndas developing super compstatins for complement-mediated disorders

on February 10, 2014

On February 10, 2014, in the article entitled “Amyndas: Complement shutdown,” Amyndas Pharmaceuticals was presented in BioCentury as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders that could be more potent than other complement inhibitors.

To read article: www.biocentury.com

Latest News

  • Iatronet.gr: Φάρμακο με ελληνική “υπογραφή” για τη γεωγραφική ατροφία ωχράς κηλίδας

  • EUSTM (9th Congress): Novel Transformative Treatment for Periodontal Disease

  • Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2023 - Amyndas Pharmaceuticals. All Rights Reserved.